References
- 1. M. Song, Recent developments in small molecule therapies for renal cell carcinoma, Eur. J. Med. Chem.142 (2017) 383–392; https://doi.org/10.1016/j.ejmech.2017.08.007
- 2. P. Mendiratta, B. I. Rini and M. C. Ornstein, Emerging immunotherapy in advanced renal cell carcinoma, Urol. Oncol.35 (2017) 687–693; https://doi.org/10.1016/j.urolonc.2017.08.011
- 3. S. M. Yu, D. H. Hu and J. J. Zhang, Umbelliferone exhibits anticancer activity via the induction of apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells, Mol. Med. Rep.12 (2015) 3869–3873; https://doi.org/10.3892/mmr.2015.3797
- 4. D. Li, N. Wang, J. Zhang, S. Ma, Z. Zhao and E. M. Ellis, Hepatoprotective effect of 7-hydroxycou-marin against methyl glyoxal toxicity via activation of Nrf2, Chem. Biol. Interact.276 (2017) 203–209; https://doi.org/10.1016/j.cbi.2017.02.020
- 5. A. Bondev, T. Bondeva and R. Wetzker, Regulation of phosphoinositide 3-kinase γ protein kinase activity in vitro and in COS-7 cells, Signal Transduction1 (2015) 79–85.
- 6. H. Guo, P. German, S. Bai, S. Barnes, W. Guo, X. Oi, H. Lou, J. Liang, E. Jonasch, G. B. Mills and Z. Ding, The PI3K/AKT Pathway and renal cell carcinoma, J. Genet. Genomics42 (2015) 343–353; https://doi.org/10.1016/j.jgg.2015.03.003
- 7. U. Maier, A. Babich and B. Nurnberg, Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma, J. Biol. Chem.274 (1999) 29311–29317.
- 8. M. M. Kaneda, K. S. Messer, N. Ralainirina, H. Li, C. J. Leem, S. Gorjestani, G. Woo, A. V. Nguyen, C. C. Figueiredo, P. Foubert, M. C. Schmid, M. Pink, D. G. Winkler, M. Rausch, V. J. Palombella, J. Kutok, K. McGovern, K. A. Frazer, X. Wu, M. Karin, R. Sasik, E. E. Cohen and J. A. Varner, PI3Kγ is a molecular switch that controls immune suppression, Nature539 (2016) 437–442; https://doi.org/10.1038/nature19834
- 9. M. E. Marshall, K. Kervin, C. Benefield, A. Umerani, S. Albainy-Jenei, Q. Zhao and M. B. Khazaeli, Growth-inhibitory effects of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin on human malignant cell lines in vitro, J. Cancer Res. Clin. Oncol.120 Suppl. (1994) S3-10.
- 10. A. Vijayalakshmi and G. Sindhu, Umbelliferone arrest cell cycle at G0/G1 phase and induces apoptosis in human oral carcinoma (KB) cells possibly via oxidative DNA damage, Biomed. Pharmacotherapy92 (2017) 661–671; https://doi.org/10.1016/j.biopha.2017.05.128
- 11. J. S. Lopez-Gonzalez, H. Prado-Garcia, D. Aguilar-Cazares, J. A. Molina-Guarneros, J. Morales-Fuentes and J. J. Mandoki, Apoptosis and cell cycle disturbances induced by coumarin and 7-hydroxycoumarin on human lung carcinoma cell lines, Lung Cancer43 (2004) 275–283; https://doi.org/10.1016/j.lungcan.2003.09.005
- 12. F. A. Jiménez-Orozco, J. S. López-González, A. Nieto-Rodriguez, M. A. Velasco-Velázquez, J. A. Molina-Guarneros, N. Mendoza-Patiño, M. J. García-Mondragón, P. Elizalde-Galvan, F. León-Cedeño and J. J. Mandoki, Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin, Lung Cancer34 (2001) 185–194.
- 13. C. M. Elinos-Baez, F. Leon and E. Santos, Effects of coumarin and 7OH-coumarin on bcl-2 and Bax expression in two human lung cancer cell lines in vitro, Cell Biol. Int.29 (2005) 703–708; https://doi.org/10.1016/j.cellbi.2005.04.003
- 14. A. Akinleye, P. Avvaru, M. Furqan, Y. Song and D. Liu, Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics, J. Hematol. Oncol.6 (2013) 88; https://doi.org/10.1186/1756-8722-6-88
- 15. S. Zhu, M. B. Cohen, J. D. Bjorge, J. W. Mier and D. C. Cho, PI3K inhibition potentiates Bcl-2-dependent apoptosis in renal carcinoma cells, J. Cell Mol. Med.17 (2013) 377–385; https://doi.org/10.1111/jcmm.12019